In total population, significant elevation in HDL-C, significant lowering of alkaline phosphatase

18% RRR (hazard ratio 0.82) for 3-point MACE in total population (primary endpoint), p=0.11

21% RRR (hazard ratio 0.79) for 3-point MACE in total population (pre-specified sensitivity analysis excluding deaths of undetermined cause), p=0.06.

No appreciable difference for 3-point MACE sub-group analysis between sex, statins or baseline HbA1c above or below the median.

Apabetalone reduced MACE with 40% RRR (hazard ratio 0.6) in those with baseline LDL-C below median, but not in those with baseline LDL-C above median (hazard ratio 1.06). This one is kind of a head scratcher for me right now.....

Apabetalone reduced MACE with 50% RRR (hazard ratio 0.50) in those with baseline eGFR<60, but only by 6% RRR (hazard ratio 0.94) in those with baseline eGFR>60.

Forest plot shows consistent benefit of apabetalone for forest plot of various secondary event endpoints. What stands out is the 41% RRR (hazard ratio 0.59) in total population for first hospitalization for congestive heart failure.

A lot of positives here. 

BDAZ